GlassScriptPhysician profile
Rasha Botros
NPI 1598351835
$8,633.13
in general payments reported to CMS, 2019-2025
26 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,455 · 2022: $2,244 · 2023: $1,001 · 2024: $1,645 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,917 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,917.26 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,831.37 | 2021-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,672.91 | 2021-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $795.82 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.90 | 2021-2024 | Ofev |
| Jazz Pharmaceuticals INC. | $507.30 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.67 | 2021-2025 | Glassia |
| Amgen INC. | $381.17 | 2022-2023 | Tezspire |
| Grifols USA, LLC | $347.58 | 2021-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $335.39 | 2021-2025 | |
| Insmed, INC. | $260.32 | 2024-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $230.59 | 2021-2022 | |
| Viatris Specialty LLC | $189.27 | 2025 | Yupelri |
| Pulmonx Corporation | $148.93 | 2024-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Mallinckrodt Hospital Products INC. | $148.33 | 2022-2025 | Acthar |
| Axsome Therapeutics, INC. | $130.91 | 2024-2025 | Sunosi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $125.45 | 2021 | |
| Mylan Specialty L.P. | $118.49 | 2024 | Yupelri |
| Vifor Pharma, INC. | $86.93 | 2024-2025 | Zemaira |
| Harmony Biosciences LLC | $78.87 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $69.11 | 2024-2025 | Lumryz |
| Baxter Healthcare | $66.99 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $62.80 | 2025 | Vest Therapy Und |
| Fisher & Paykel Healthcare INC | $46.04 | 2023-2024 | Fisher & Paykel Healthcare |
| Lilly USA, LLC | $38.94 | 2025 | Zepbound |
| Vapotherm INC | $20.92 | 2022 | |
| 3b Medical, INC. | $15.13 | 2024 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasha Botros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.